Developer docs
API playgroundTry for free, no card

Search company profiles

Blue Fin Group

Full company profile

uuid000bewc

Namestring
Blue Fin Group
Websiteurl
consultbfg.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Blue Fin Group is a privately held management and consulting firm serving the pharmaceutical and biotechnology industry. According to available firmographic data, the company was founded in 2001, is headquartered in New York, United States, and operates with a headcount of 101-250 employees—placing it in the mid-sized specialist consultancy tier rather than among global generalist advisory firms. Its self-description characterizes the business as management consulting for pharma and biotech, but the underlying service lines (e.g., commercial strategy, market access, operations, launch readiness), engagement model, and technology stack could not be verified from the supplied sources.

The primary website (consultbfg.com) returned only a verification/loading page during data collection, and no press releases, case studies, customer references, or third-party coverage were available to substantiate product details, pricing structure, or go-to-market mechanics. Consequently, whether Blue Fin Group operates on a pure advisory (time-and-materials or fixed-fee consulting) basis, retains proprietary tools or frameworks, or has expanded into productized offerings cannot be determined from the evidence on hand. The 24 years of operating history and a 101-250 employee footprint imply a mature, established practice rather than an early-stage venture, but no financial, growth, or strategic-move data is present to corroborate this.

For an investment audience, the key takeaway is that the firm sits in a defensible niche (life-sciences management consulting) but the supplied evidence is too thin to support deeper diligence conclusions on revenue, customer base, competitive positioning, or growth trajectory without primary research.

Short descriptiontext

Blue Fin Group is a privately held US management and consulting firm serving the pharmaceutical and biotechnology industry. Founded in 2001 and headquartered in New York, it operates with 101-250 employees as a mid-sized specialist life-sciences consultancy.

Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pharmaceutical consulting, biotech consulting, life sciences advisory, pharma management consulting, healthcare consulting
Industry1 code
PRIMARYBPAHADAB
Corporate Finance & Capital Advisory
Product category
Pharmaceutical Consulting
Social media profiles1 record
Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Blue Fin Group is a management and consulting company that provides advisory services to clients in the pharmaceutical and biotechnology industry. The firm supports pharma and biotech organizations with management consulting engagements from its New York headquarters.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product or service information for Blue Fin Group was found in the provided source data. The available sources do not contain specific details about Blue Fin Group's offerings, product portfolio, or service descriptions.

Product and service1 record
1Management Consulting Services
CategoryPharmaceutical Consulting
Description

Advisory and management consulting services delivered to pharmaceutical and biotechnology companies, supporting business and strategic needs across the life-sciences value chain.

No data
Peers10 records
1ZS Associates
TypeDirect peer
Description

Global consulting firm specialized in the pharmaceutical and biotech industry with deep commercial, R&D, and analytics practices. Directly comparable to BFG in vertical specialization and pharma-focused advisory offerings.

TypeBroad incumbent
Description

The largest scaled provider of pharma and biotech advisory, analytics, and consulting services globally. A broad incumbent whose pharma consulting practice overlaps directly with BFG's positioning.

TypeDirect peer
Description

Boutique-to-mid-sized consulting firm focused exclusively on the life-sciences industry with strategy and commercial practice areas. Direct peer in vertical specialty and firm-size profile.

TypeDirect peer
Description

Global strategy consulting firm with one of the strongest dedicated life-sciences practices (LEK Healthcare). Competes with BFG for similar pharma and biotech strategy engagements.

TypeDirect peer
Description

Consulting firm with a prominent life-sciences practice serving pharma and biotech clients on commercial strategy, pricing, and litigation support. Comparable in advisory scope and client base.

TypeDirect peer
Description

Global consulting firm with leading pharma pricing, market access, and commercial strategy practices. A direct competitor for pharma and biotech clients with a similar specialty lens.

TypeBroad incumbent
Description

Largest global strategy consultancy with a dedicated pharma and medical products practice that competes for the same enterprise pharma/biotech mandates as BFG, often at larger scale.

TypeBroad incumbent
Description

Top-tier strategy consultancy with a substantial healthcare and life-sciences practice serving pharma and biotech clients on commercial and corporate strategy. A broad incumbent peer.

TypeDirect peer
Description

Boutique life-sciences strategy consulting firm focused exclusively on pharma, biotech, and medical technology clients. Strong overlap with BFG in niche life-sciences strategy advisory.

TypeBroad incumbent
Description

Large advisory firm with a dedicated life-sciences consulting practice covering pharma strategy, operations, and commercialization. Broad incumbent competing for similar pharma engagements.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blue Fin Group

Pharmaceutical Consultingconsultbfg.com

Blue Fin Group is a privately held US management and consulting firm serving the pharmaceutical and biotechnology industry. Founded in 2001 and headquartered in New York, it operates with 101-250 employees as a mid-sized specialist life-sciences consultancy.

What Blue Fin Group does

Blue Fin Group is a privately held management and consulting firm serving the pharmaceutical and biotechnology industry. According to available firmographic data, the company was founded in 2001, is headquartered in New York, United States, and operates with a headcount of 101-250 employees—placing it in the mid-sized specialist consultancy tier rather than among global generalist advisory firms. Its self-description characterizes the business as management consulting for pharma and biotech, but the underlying service lines (e.g., commercial strategy, market access, operations, launch readiness), engagement model, and technology stack could not be verified from the supplied sources.

The primary website (consultbfg.com) returned only a verification/loading page during data collection, and no press releases, case studies, customer references, or third-party coverage were available to substantiate product details, pricing structure, or go-to-market mechanics. Consequently, whether Blue Fin Group operates on a pure advisory (time-and-materials or fixed-fee consulting) basis, retains proprietary tools or frameworks, or has expanded into productized offerings cannot be determined from the evidence on hand. The 24 years of operating history and a 101-250 employee footprint imply a mature, established practice rather than an early-stage venture, but no financial, growth, or strategic-move data is present to corroborate this.

For an investment audience, the key takeaway is that the firm sits in a defensible niche (life-sciences management consulting) but the supplied evidence is too thin to support deeper diligence conclusions on revenue, customer base, competitive positioning, or growth trajectory without primary research.

Blue Fin Group firmographics

Firmographics
Name
Blue Fin Group
Website
https://consultbfg.com
Company type
Private
Founded year
2001
Headcount range
101–250 employees
Short description
Blue Fin Group is a privately held US management and consulting firm serving the pharmaceutical and biotechnology industry. Founded in 2001 and headquartered in New York, it operates with 101-250 employees as a mid-sized specialist life-sciences consultancy.
Ownership category
akta.pro rank

Blue Fin Group industry classification

Industry
Product category
Pharmaceutical Consulting
akta.pro industry
PRIMARYBPAHADAB
Corporate Finance & Capital Advisory

Keywords

  • Pharmaceutical consulting
  • Biotech consulting
  • Life sciences advisory
  • Pharma management consulting
  • Healthcare consulting

Where Blue Fin Group is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Blue Fin Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Blue Fin Group product offering

Product offering

Core offering

Blue Fin Group is a management and consulting company that provides advisory services to clients in the pharmaceutical and biotechnology industry. The firm supports pharma and biotech organizations with management consulting engagements from its New York headquarters.

Product overview

No product or service information for Blue Fin Group was found in the provided source data. The available sources do not contain specific details about Blue Fin Group's offerings, product portfolio, or service descriptions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Management Consulting Services Advisory and management consulting services delivered to pharmaceutical and biotechnology companies, supporting business and strategic needs across the life-sciences value chain.

Companies that use Blue Fin Group

Customer profile

Ideal customer profiles1 record

Blue Fin Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Blue Fin Group competitors and assessment

Company assessment

Direct peers

  • ZS Associates: Global consulting firm specialized in the pharmaceutical and biotech industry with deep commercial, R&D, and analytics practices. Directly comparable to BFG in vertical specialization and pharma-focused advisory offerings.
  • Putnam Associates: Boutique-to-mid-sized consulting firm focused exclusively on the life-sciences industry with strategy and commercial practice areas. Direct peer in vertical specialty and firm-size profile.
  • LEK Consulting: Global strategy consulting firm with one of the strongest dedicated life-sciences practices (LEK Healthcare). Competes with BFG for similar pharma and biotech strategy engagements.
  • Charles River Associates: Consulting firm with a prominent life-sciences practice serving pharma and biotech clients on commercial strategy, pricing, and litigation support. Comparable in advisory scope and client base.
  • Simon-Kucher & Partners: Global consulting firm with leading pharma pricing, market access, and commercial strategy practices. A direct competitor for pharma and biotech clients with a similar specialty lens.
  • ClearView Healthcare Partners: Boutique life-sciences strategy consulting firm focused exclusively on pharma, biotech, and medical technology clients. Strong overlap with BFG in niche life-sciences strategy advisory.

Broad incumbents

  • IQVIA: The largest scaled provider of pharma and biotech advisory, analytics, and consulting services globally. A broad incumbent whose pharma consulting practice overlaps directly with BFG's positioning.
  • McKinsey & Company (Pharmaceuticals & Medical Products Practice): Largest global strategy consultancy with a dedicated pharma and medical products practice that competes for the same enterprise pharma/biotech mandates as BFG, often at larger scale.
  • Bain & Company (Healthcare Practice): Top-tier strategy consultancy with a substantial healthcare and life-sciences practice serving pharma and biotech clients on commercial and corporate strategy. A broad incumbent peer.
  • Guidehouse (formerly Navigant Consulting): Large advisory firm with a dedicated life-sciences consulting practice covering pharma strategy, operations, and commercialization. Broad incumbent competing for similar pharma engagements.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Blue Fin Group social profiles

Digital presence

Blue Fin Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blue Fin Group leadership team

Management profile

Number of profiles

Blue Fin Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blue Fin Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blue Fin Group

What does Blue Fin Group do?

Blue Fin Group is a management and consulting company that provides advisory services to clients in the pharmaceutical and biotechnology industry. The firm supports pharma and biotech organizations with management consulting engagements from its New York headquarters.

When was Blue Fin Group founded?

Blue Fin Group was founded in 2001. It employs 101 to 250 people.

Where is Blue Fin Group based?

Blue Fin Group is headquartered in New York, United States, in the North America region.

Who are Blue Fin Group's main competitors?

Direct peers on record are ZS Associates, Putnam Associates, LEK Consulting, Charles River Associates, Simon-Kucher & Partners and ClearView Healthcare Partners. Broad incumbents are IQVIA, McKinsey & Company (Pharmaceuticals & Medical Products Practice), Bain & Company (Healthcare Practice) and Guidehouse (formerly Navigant Consulting).

Does Blue Fin Group have an API?

No public API is recorded for Blue Fin Group.

What industry is Blue Fin Group in?

Blue Fin Group's product category is Pharmaceutical Consulting. Its primary akta.pro industry code is BPAHADAB, Corporate Finance & Capital Advisory.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBlue Fin Group, an IntegriChain Company, Promotes Jason Bogroff to PartnerBlue Fin Group, a management consulting firm serving the Life Sciences industry and an IntegriChain company, announced the promotion of Jason Bogroff to Partner with direct client responsibility and leadership of the firm's Data Strategy area of focus. Bogroff joined the firm in 2006 and has developed proprietary consulting methodology while working across pharmaceuticals, medical devices, and consumer health sectors. The promotion comes as Blue Fin Group expands its consulting role within IntegriChain.PR NewswireBlue Fin Group Presents Market Research Study on Current and Future Payer Management in OncologyBlue Fin Group, a pharmaceutical management consulting firm and IntegriChain company, announced a new market research study on current and future payer management in oncology. The study provides quantitative and qualitative data on payer decision-making factors, top barriers, and management expectations over the next three years, including increasing preference for value-based contracting. The research is based on an award-winning poster presented at AMCP Nexus in October 2021.PR NewswireBlue Fin Group, an IntegriChain Company, Promotes Reena K. Patel to PartnerBlue Fin Group promoted Reena K. Patel to Partner, effective April 1, 2022. She joined in 2011 and focuses on product commercialization, market access, and government pricing. The promotion follows IntegriChain's acquisition, which now supports about 400 manufacturers.PR NewswireIntegriChain Acquires Blue Fin Group, Combining Therapy Commercialization Expertise with Leading Technology, Data, and Business OperationsIntegriChain acquired Blue Fin Group, a market access consulting firm, combining its expertise with IntegriChain's technology and data capabilities. The combined workforce spans nearly 600 professionals, and Blue Fin Group will remain a separate operating entity with no changes to customer services.ConsultbfgChoosing a Third-Party Logistics (3PL) Partner – A Critical First StepA case study describes how a new pharmaceutical manufacturer launching a branded self-administered cold-chain specialty product used a requirements-driven assessment process to select a third-party logistics partner. Blue Fin Group facilitated cross-functional alignment, RFP analysis, financial modeling and capabilities review, leading to a partner meeting call center, order-to-cash and data reporting needs. The client later shifted to a non-title model as benchmarks were met.